Exin Therapeutics

unknown
unknown
Stage
1
Investors

About

Exin Therapeutics uses AI-trained multimodal models and high-throughput in‑house mouse studies to discover therapeutics that modulate neural activity. Its initial programs target epilepsies associated with autism and Parkinson’s disease.

Explore Exin Therapeutics's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.